Kawartha Centre - Redefining Healthy Aging

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease13 trials

Phase

• Phase 312 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Terminated5 trials
• Completed3 trials

Lead sponsor

• Alzheon Inc.2 trials
• Biogen2 trials
• Cassava Sciences, Inc.2 trials
• Eli Lilly and Company2 trials
• AriBio Co., Ltd.1 trial
• and 4 more

Running trials

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

Closed trials

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Alzheon Inc.· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Alzheon Inc.· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

  NCT03402503· Phase 2· IntelGenx Corp.· Source